Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novo data buttress its oral semaglutide case, this time in kidney-impaired patients

fiercepharmaAugust 21, 2018

Tag: novo , Oral Semaglutide

PharmaSources Customer Service